Faculty of 1000 evaluation for Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Blood ◽

10.1182/blood-2012-07-440974 ◽

2013 ◽

Vol 121 (5) ◽

pp. 745-751 ◽

Cited By ~ 64

Author(s):

James L. Rubenstein ◽

Jing Li ◽

Lingjing Chen ◽

Ranjana Advani ◽

Jan Drappatz ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Phase 1 ◽

Cns Lymphoma ◽

Phase 1 Trial ◽

Multicenter Phase ◽

Key Points

Key Points Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma.

Faculty Opinions recommendation of Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006667.793477593 ◽

2013 ◽

Author(s):

Luca Persani

Keyword(s):

Thyroid Cancer ◽

Phase 1 ◽

Anaplastic Thyroid Cancer ◽

Phase 1 Trial ◽

Ppar Γ ◽

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2013-1106 ◽

2013 ◽

Vol 98 (6) ◽

pp. 2392-2400 ◽

Cited By ~ 62

Author(s):

R. C. Smallridge ◽

J. A. Copland ◽

M. S Brose ◽

J. T. Wadsworth ◽

Y. Houvras ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase 1 ◽

Anaplastic Thyroid Cancer ◽

Phase 1 Trial ◽

Ppar Γ ◽

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial

European Journal of Cancer ◽

10.1016/j.ejca.2018.07.297 ◽

2018 ◽

Vol 101 ◽

pp. S34 ◽

Cited By ~ 3

Author(s):

Christiane Querfeld ◽

John A. Thompson ◽

Matthew Taylor ◽

Raju Pillai ◽

Lisa DS. Johnson ◽

...

Keyword(s):

Antitumor Activity ◽

Mycosis Fungoides ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitor ◽

Checkpoint Inhibitor ◽

Phase 1 ◽

Intralesional Injection ◽

Sézary Syndrome ◽

Phase 1 Trial ◽

Decision letter for "A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults"

10.1002/jbmr.4016/v3/decision1 ◽

2020 ◽

Keyword(s):

Phase 1 ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Review for "A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults"

10.1002/jbmr.4016/v1/review2 ◽

2019 ◽

Keyword(s):

Phase 1 ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Case Medical Research ◽

10.31525/ct1-nct04049825 ◽

2019 ◽

Author(s):

Keyword(s):

Phase 1 ◽

A Phase 1 Trial to Evaluate the Male Reproductive Safety of Pretomanid in Healthy Volunteers

Case Medical Research ◽

10.31525/ct1-nct04179500 ◽

2019 ◽

Author(s):

Keyword(s):

Healthy Volunteers ◽

Phase 1 ◽

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Case Medical Research ◽

10.31525/ct1-nct04234048 ◽

2020 ◽

Author(s):

Keyword(s):

T Cell ◽

Hodgkin Lymphoma ◽

Phase 1 ◽

Phase 1 Trial ◽

Non Hodgkin Lymphoma

Faculty Opinions recommendation of Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718514018.793503131 ◽

2015 ◽

Author(s):

Qing Zhong

Keyword(s):

Phase 1 ◽

Proteasome Inhibition ◽